Key facts
- Modulo Bio’s last known valuation is $45.0M (Nov 2024).
- It has raised $22.6M across 2 recorded rounds; the latest was Early Stage VC ($5.8M) in Nov 2024.
- Notable investors include Creative Destruction Lab, Google for Startups, Mana Ventures, Calm Ventures, University of Toronto — 15 tracked in total.
- Modulo Bio has filed 2 Form Ds with the SEC since 2021, most recently Nov 2024 ($5.8M sold to 3 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Modulo Bio
Funding rounds
2 roundsAbout Modulo Bio
Developer of digital biology mechanisms designed to accelerate the discovery of therapeutic targets harnessing autoimmunity. The company offers stem cell engineering that generates human microglia-centered neuroimmune microenvironments from stem cells to manipulate and measure the neuroimmune system in cell models and from patient samples, enabling healthcare professionals to identify new treatment paths for neurodegenerative diseases.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2021
- Employees
- 10
- Website
- modulo.bio/
- Ownership
- Privately Held (backing)
Modulo Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Modulo Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Modulo Bio in its N-PORT filings yet. We sweep new filings monthly.